CEVEC Strengthens Team to Execute Rapid Growth Strategy

– Dr. Nico Scheer appointed as Vice President Business Development

– Dr. Hartmut Tintrup appointed as Vice President Business Development
Gene Therapy and Viruses

– Headcount increased by 40% since May 2015

COLOGNE, Germany–(BUSINESS WIRE)–CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of
tailor-made recombinant glycoproteins and gene therapy vectors, today
announced the expansion and reorganization of its management team.

Dr. Nico Scheer will join the Company as Vice President Business
Development Glycoproteins as of November 1, 2015. Dr. Scheer will be
responsible for CEVEC’s growth strategy in the Company’s CAP(R)Go
activities. Dr. Hartmut Tintrup, currently Chief Business Officer, moves
to the position of Vice President Business Development Gene Therapy and
Viruses in which he will be responsible for the growth of CEVEC’s
CAP(R)GT business. Both will be reporting to CEO Frank Ubags.

Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH,
commented, “Following our focus on glycoproteins and gene therapy
vectors in May 2015 and the subsequent successful co-operations, we have
increased our overall headcount by 40% and attracted competent, talented
people in the scientific, quality assurance and regulatory business
fields. We are experiencing an exponentially increasing demand for our
CAP(R)Go portfolio in the field of glycoproteins and for our CAP(R)GT
technology for the industrial scale production of gene therapy vectors.
With this strengthening and restructuring of the management team, we are
now well placed to further accelerate the growth of our Company.”

“It’s an exciting time to join CEVEC, as the Company is poised to take
advantage of significant growth and expansion opportunities to build
market leadership in the production of tailor-made recombinant
glycoproteins,” added Dr. Nico Scheer. “I am delighted to
get the opportunity to identify and form alliances that unlock the full
potential of CEVEC’s unique CAP(R)Go Technology.”

Prior to joining CEVEC, Dr. Scheer served in different leading
management positions within Artemis Pharmaceuticals GmbH, TaconicArtemis
GmbH and Taconic Biosciences GmbH – most recently as Director Business
Development and Head of tADMET portfolio. Dr. Scheer adds more than 10
years of experience in business development, portfolio and project
management, plus licensing and partnering activities in the life science
industry as well as a strong scientific background in drug metabolism,
molecular biology, and in vitro technologies. He holds a PhD in
Molecular Developmental Biology and a PMI certified Project Management
Professional (PMP).

About CEVEC:

Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company’s core technologies, CAP(R)Go and CAP(R)GT are
based on a unique human cellular expression system.

The CAP(R)Go expression platform comprises a portfolio of
glyco-optimized human suspension cell lines for tailor-made
glycosylation of recombinant proteins. The cells are highly efficient
for the production of a broad range of difficult to express
glyco-proteins and provide authentic human post-translational
modifications. CAP(R)Go has proven to enhance the activity, stability
and serum half-life of several candidate proteins.

The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow
to high cell densities and show a broad viral propagation spectrum
including lentivirus (LV), adenovirus (AV) and adeno-associated virus
(AAV). Furthermore, CAP(R)GT enables easier scale-up and reduced
production costs when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and
biotechnology partners followed by licensing agreements for the
technology form one revenue base for CEVEC. In addition, the Company
provides contract manufacturing for the GMP production in CAP(R)Go and
CAP(R)GT cells.



CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive
T.:+49 221 46020800
E.: ubags@cevec.com
Services AG

Anne Hennecke
Public Relations
T.: +49
211 52925222
E.: anne.hennecke@mc-services.eu